Sterile inflammation is an essential factor causing hepatic ischemia/reperfusion (I/R) injury. As a critical regulator of inflammation, the role of monocyte chemoattractant protein-induced protein 1 (MCPIP1) in hepatic I/R injury remains undetermined. In this study, we discovered that MCPIP1 downregulation was associated with hepatic I/R injury in liver transplant patients and a mouse model. Hepatocyte-specific Mcpip1 gene knockout and transgenic mice demonstrated that MCPIP1 functions to ameliorate liver damage, reduce inflammation, prevent cell death, and promote regeneration. A mechanistic study revealed that MCPIP1 interacted with and maintained hypoxia-inducible factor 1α (HIF-1α) expression by deubiquitinating HIF-1α. Notably, the HIF-1α inhibitor reversed the protective effect of MCPIP1, whereas the HIF-1α activator compensated for the detrimental effect of MCPIP1 deficiency. Thus, we identified the MCPIP1-HIF-1α axis as a critical pathway that may be a good target for intervention in hepatic I/R injury. (Hepatology 2018;68:2362-2379).
H epatic ischemia/reperfusion (I/R) injury involves the two interrelated phases of local ischemic insult and inflammation-mediated reperfusion injury.
(1) During the ischemic period, the liver is deprived of oxygen and nutrients, leading to cellular metabolism breakdown. Following blood flow restoration (reperfusion), more severe damage is provoked due to the propagation of inflammation and cell death.
(2) The overall mechanisms of hepatic I/R injury are highly complex and involve the intertwining of multiple cell types and molecular pathways, which may explain the difficulty of developing therapeutic strategies that can be translated into clinical application. (3, 4) Thus, further dissecting the molecular mechanism of hepatic I/R injury is urgently needed to unveil potential targets for developing therapeutic strategies.
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Monocyte chemoattractant protein-induced protein 1 (MCPIP1), a zinc-finger protein encoded by the ZC3H12A gene, was initially discovered as the most highly induced mRNA by monocyte chemotactic protein-1 (MCP-1) in human peripheral blood monocytes. (5) Emerging evidence indicates that MCPIP1 plays an important role in many processes, such as promotion of angiogenesis, (6) inhibition of macrophage activation, (7) attenuation of myocardial dysfunction, (8) and induction of cardiomyoblast death. (9) Mice that are deficient in MCPIP1 develop a complex phenotype including autoimmune disorders, anemia, and a severe inflammatory response. (10) Interestingly, MCPIP1 possesses both endoribonuclease (RNase) and deubiquitinating enzyme (DUB) activities. For instance, MCPIP1 promotes the degradation of inflammatory cytokines' mRNAs, including IL-6 and IL-1. (10) It also removes ubiquitin moieties attached to proteins such as TNF receptor associated factor (TRAF) 2, 3 and 6, and subsequently suppresses c-Jun N-terminal kinase ( JNK) and nuclear factor kappa B (NF-κB) signaling pathways. (11) MCPIP1 can even act as a transcription factor participating in the development of ischemic heart disease and cardiomyocyte apoptosis caused by oxidative stress. (12) Considering the critical role of inflammatory response and NF-κB signaling in hepatic I/R injury, MCPIP1 may affect hepatic I/R injury by modulating these biological processes. Nevertheless, the underlying mechanism has not been investigated.
Multiple proteins are substrates of MCPIP1. One of them, hypoxia-inducible factor 1α (HIF-1α), is a transcription factor regulating diverse biological processes such as tumorigenesis, metabolism, and angiogenesis. (13, 14) Physiologically, HIF-1α is proline-hydroxylated by prolyl hydroxylase domain (PHD) enzymes and subsequently ubiquitinated by von Hippel-Lindau for degradation through the ubiquitin-proteasome pathway. (14) (15) (16) HIF-1α activation has been documented in multiple pathological conditions through different mechanisms. (17) (18) (19) (20) (21) (22) (23) (24) Particularly, HIF-1α is a protective factor in hepatic I/R injury, (25) and pharmacological stabilization of HIF-1α protects against myocardial I/R injury. (26, 27) Interestingly, HIF-1α is stabilized by MCPIP1. (28) However, whether HIF-1α is required for MCPIP1 function remains unknown.
In this study, we observed a tight association of MCPIP1 downregulation with hepatic I/R injury. MCPIP1 protected against hepatic I/R injury through deubiquitinating and stabilizing HIF-1α. Thus, we identify MCPIP1 as a protective factor in hepatic I/R injury.
Materials and Methods

aNIMalS aND tReatMeNtS
All of the mice (male, 8-10 weeks old) were housed in a specific pathogen-free and temperature-controlled (23 ± 2°C) environment with a 12-hour light/dark cycle. The animals were provided humane care based on the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication 86-23, revised in 1985). All animal experiments were approved by the Animal Care and Use Committee of Renmin Hospital of Wuhan University.
Mcpip1-floxed mice (Flox) were generated using CRISPR/Cas9 methods as previously described. (29) aRtICle INFoRMatIoN:
Two single-guide RNAs (sg1 and sg2) targeting Mcpip1 intron 2 and intron 3 were designed. The donor vector contained exon 3 flanked by two loxPsites and two homology arms as templates for homologous recombination (Supporting Fig. S1A ). Hepatocytespecific Mcpip1 knockout mice (HKO) were obtained by crossing Mcpip1-floxed mice with albumin-Cre transgenic mice ( Jackson Laboratory, Bar Harbor, ME) on the C57BL background. A construct containing full-length Mcpip1 complementary DNA (cDNA) downstream of the CAG-loxP-CAT-loxP cassette was used for microinjection into mouse embryos to generate transgenic mice. The transgenic mice were further crossed with albumin-Cre mice to generate Mcpip1 transgenic mice with hepatocyte-specific expression (HTG) (Supporting Fig. S1C ). Polymerase chain reaction-based genotyping was performed using the primer pairs listed in Supporting Table S1 .
A partial liver warm ischemia model was developed as previously described. (30) In brief, mice were anesthetized with pentobarbital sodium (50 mg/kg). A midline laparotomy was performed, and an atraumatic clip (Fine Science Tools, North Vancouver, Canada) was placed across the portal vein, hepatic artery, and bile duct to interrupt blood supply to the left lateral/ median lobes (∼70%) of the liver. Sham-operated mice were treated with the same operative procedure without clipping the blood vessels. After ischemia for 60 minutes and reperfusion for different times, animals were sacrificed, and the serum and liver samples were immediately collected for further analysis.
HuMaN lIVeR SaMpleS
All human liver ischemia/reperfusion samples were collected from liver transplant patients at Renmin Hospital of Wuhan University. Control liver samples were biopsied from healthy donors without hepatitis and steatosis. Informed consent was voluntarily signed by each donor or family member. No samples from executed prisoners or institutionalized persons were used in the experiments. All of the human experiments were approved by the Review Board of Renmin Hospital of Wuhan University and were in accordance with the principles of the Declaration of Helsinki. In total, six human liver ischemia/reperfusion samples (n = 6) and three healthy control liver samples (n = 3) were used in this study.
Cell CultuRe aND HepatoCyte HypoXIa/ Re-oXygeNatIoN MoDel
Primary hepatocytes were isolated as described previously. (31, 32) The isolated cells were seeded and cultured overnight in complete DMEM/F12. After changing the medium to serum-free and glucose-free DMEM/F12, cellular hypoxic conditions were created in a modular incubator chamber (Biospherix, Lacona, NY) and maintained by continuous gas flow with a 1% O 2 , 5% CO 2 and 94% N 2 gas mixture. After 60 minutes of hypoxia, cells were incubated under normal conditions (95% air and 5% CO 2 ) for the indicated times.
The specif ic inhibitor 2-methoxyestradiol (2-MeOE2 or 2ME2, 100 μM, S1233; Selleck, Shanghai, China) or dimethyloxalylglycine (DMOG, 100 μM, S7483; Selleck), used to suppress or activate HIF-1α, respectively, was added to the culture medium of HKO, HTG, or the corresponding control hepatocytes prior to the hypoxia/re-oxygenation operation. The same volume of dimethyl sulfoxide (DMSO) was used as vehicle control. Cell viability was assessed by the MTT (methyl-thiazol-tetrazolium) Cell Viability Assay Kit (Abnova; Jhongli, Taiwan, China). Cell cytotoxicity was assessed by measuring lactate dehydrogenase (LDH) release into the medium by necrotic cells using an LDH Cytotoxicity Assay Kit (Promega, Madison, WI).
FloW CytoMetRy aNalySIS oF NoNpaReNCHyMal CellS
The liver nonparenchymal cells (NPCs) of mice subjected to sham or I/R operation were isolated as previously described. (31, 32) Cells were incubated withanti-CD16/32 antibody (mAb, clone 93) to blocknonspecific binding of NPCs to the Fcγ receptor. Next, these NPCs were incubated with allophycocyanin-labeled anti-F4/80 antibody (clone BM8; Biolegend, San Diego, CA), phycoerythrin-conjugated anti-Ly6G antibody (clone 1A8), and PerCP/Cy5.5-conjugated anti-CD11b antibody (clone M1/70). The flow cytometry was performed with a BD FACSVerse Flow Cytometer (BD Biosciences, San Jose, CA), and data were analyzed with FlowJo (Tree Star, Ashland, OR).
lIVeR BIoCHeMICal MeaSuReMeNt
The extent of liver damage in living animals was evaluated by measuring the alanine amino transferase (ALT) and aspartate amino transferase (AST) activities in the serum with the ADVIA 2400 Chemistry System (Siemens, Tarrytown, NY). The serum and medium cytokines were detected with commercial ELISA kits (Peprotech, Rocky Hill, NJ; R&D Systems, Minneapolis, MN) according to the manufacturers' protocols.
HIStology aND IMMuNoFluoReSCeNCe StaININg
Paraffin-embedded liver sections (4 μm) were stained with hematoxylin and eosin (H&E) to evaluate the liver damage by Suzuki's score. Suzuki scoring was done blindly by a single pathologist.
Paraffin-embedded liver sections were also used for immunofluorescence as described previously. (30) After being incubated with primary antibodies against hepatocyte nuclear factor 4 (HNF4) (ab41898; Abcam, Cambridge, MA), MCPIP1 (PAB4143; 1:50; Abnova), CD3 (GA045204, Gent Tech), Ly6G (551459, BD Biosciences), and MAC-3 (550292, BD Biosciences), slides were further stained with fluorescence-labeled secondary antibodies. TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) and proliferating cell nuclear antigen (Pcna) assays were performed to assay cell death and proliferation, respectively. Images were acquired with a fluorescence microscope (OLYMPUS DX51, Tokyo, Japan) and DP2-BSW software (version 2.2, Tokyo, Japan).
Real-tIMe QuaNtItatIVe pCR aND WeSteRN Blot aNalySIS
Total RNA was extracted from liver tissues or cultured cells and quantitated with a Nanodrop 2000 (Thermo Fisher Scientific, Madison, WI). The quality of total RNA was also verified by gel electrophoresis. Total RNA (2 μg) was reverse-transcribed into cDNA using the Transcriptor First Strand cDNA Synthesis Kit (Cat No. 4896866001; Roche) according to the manufacturer's instructions. Real-time quantitative PCR (RT-PCR) was performed with SYBR Green PCR Master Mix (Cat No. 04887352001, Roche) as described previously. (30) The mRNA expression was normalized to the expression of β-actin. The primer sequences of the target genes are listed in Supporting  Table S2 . For the expression level of proteins, western blotting was performed as previously described. (30) Signals were visualized and captured by a ChemiDoc MP Imaging System (Bio-Rad). GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was used as a loading control. The antibodies used in the present study are provided in Supporting Table S3 .
StatIStICal aNalySIS
All values in this study are expressed as the mean ± SD and analyzed using SPSS 17.0 software. Statistical differences between more than two groups was determined by one-way analysis of variance (ANOVA) followed by a Bonferroni post hoc test (assuming equal variances) or Tamhane's T2 test. The statistically significant difference between two individual groups was determined with the two-tailed Student's t-test. Differences with P < 0.05 were considered significant.
Results
MCpIp1 DoWNRegulatIoN CoRRelateS to HepatIC I/R INJuRy
We measured MCPIP1 expression in liver samples from liver transplant patients to explore the potential correlation of MCPIP1 and liver I/R injury. Substantial downregulation of MCPIP1 protein was observed in livers from patient samples compared with control samples (Fig. 1A) . The protein levels of MCPIP1 in liver lobes from wild-type mice were progressively decreased from 1 to 24 hours of hepatic I/R administration (Fig. 1B) . Similarly, gradually reduced MCPIP1 protein levels were also observed in widetype primary hepatocytes subjected to 1 to 12 hours of H/R treatment (Fig. 1C) . In addition, immunofluorescence staining showed a reduced fluorescence intensity of MCPIP1, which overlapped with the hepatocyte marker HNF4 fluorescence signal (Fig. 1D) . These results suggest that MCPIP1 downregulation in hepatocytes is associated with hepatic I/R injury and that MCPIP1 may be involved in this process.
MCpIp1 ReDuCeS lIVeR DaMage IN HepatIC I/R INJuRy
We generated hepatocyte-specific HKO mice and nontransgenic [NTG] , respectively), as evidenced by increased necrotic area and Suzuki's score in the liver sections and elevated ALT and AST activities in the serum ( Fig. 2A-F) . Notably, MCPIP1 deficiency in Mcpip1-HKO mice worsened hepatic I/R injury compared with that in Flox mice, whereas sustained MCPIP1 expression in Mcpip1-HTG mice ameliorated the phenotype compared with that in NTG mice ( Fig. 2A-F) . These observations suggest that MCPIP1 is a protective regulator in hepatic I/R injury.
MCpIp1 aMelIoRateS INFlaMMatIoN IN HepatIC I/R INJuRy
Sterile inflammation is the hallmark of hepatic I/R injury.
(4) Therefore, we examined the inflammatory response in Mcpip1-HKO and Mcpip1-HTG mice after hepatic I/R operation. The Mcpip1-HKO mice exhibited more severe infiltration of T cells (Cd3 + ) and myeloid cells (Ly6g + and Mac3 + ) in the liver than Flox mice (Fig. 3A) . Flow cytometry analysis confirmed the presence of increased neutrophils and macrophages in liver from Mcpip1-HKO mice (Fig. 3B) . Moreover, serum from Mcpip1-HKO mice and medium collected from primary Mcpip1-HKO hepatocyte cultures contained higher levels of inflammatory cytokines/chemokines, including MCP-1, TNF-α, CXCL-1 (chemokine (C-X-C motif ) ligand 1), IL-1β and IL-6, than those of Flox mice, and the elevated mRNA expression level was confirmed in Mcpip1-HKO livers (Fig. 3C-E) . In contrast, Mcpip1-HTG mice exhibited less infiltration of immune cells and less inflammatory cytokine/chemokine production than NTG mice (Fig. 3A-E) . Finally, we measured p65 signaling as a marker of inflammation by western blot. Liver and hepatocytes from Mcpip1-HKO mice showed enhanced phosphorylation of IκB kinase β (IKKβ), inhibitory κB α (IκBα), and p65 and degradation of IκBα after I/R operation or H/R treatment compared with Flox mice (Fig. 3F and Supporting  Fig. S2A ). In contrast, a remarkable amelioration of inflammatory response as well as suppressed p65 signaling was observed in liver and primary hepatocytes from Mcpip1-HTG mice compared with NTG mice (Fig. 3A-F and Supporting Fig. S2A ). Collectively, these data suggest that MCPIP1 dampened inflammation in hepatic I/R injury.
MCpIp1 pRoteCtS HepatoCyteS FRoM apoptoSIS aND pRoMoteS RegeNeRatIoN
Hepatic I/R-induced excessive inflammation causes liver cell death. (33) We further explored whether MCPIP1 regulated this process. We found more TUNEL-positive cells in livers from MCPIP1-deficient mice and more LDH release from Mcpip1-HKO hepatocyte cultures than in livers from Flox mice and hepatocytes, respectively (Fig. 4A,B) . Furthermore, the increase in the pro-apoptosis genes Bcl-2-associated x protein (Bax) and cleaved casp3 and the reduction of prosurvival gene B-cell lymphoma 2 (Bcl-2) were found in Mcpip1-HKO livers or hepatocytes by RT-PCR or western blot, respectively (Fig. 4C,D) . In sharp contrast, Mcpip1-HTG mice or hepatocytes exhibited less apoptosis than NTG mice or hepatocytes, respectively (Fig. 4A-D) .
Hepatocyte death induces hepatocyte proliferation and regeneration that influence the function and prognosis of livers after I/R. As shown in Fig. 4E,F , genes promoting proliferation, such as Pcna and Ccnd1, (34) were decreased in Mcpip1-HKO livers but increased in Mcpip1-HTG livers compared with the results in Flox and NTG mice, respectively. Furthermore, MCPIP1 deficiency caused reduced cell proliferation, whereas MCPIP1 overexpression increased proliferation in primary hepatocytes subjected to hypoxia/ reoxygenation (H/R) treatment (Fig. 4G) . These results indicate that MCPIP1 protects hepatocytes from apoptosis and enhances hepatocyte proliferation/regeneration during hepatic I/R injury.
MCpIp1 BINDS to aND MaINtaINS HIF-1α pRoteIN eXpReSSIoN
As a deubiquitinase, MCPIP1 may act on multiple substrates to exert its functions. (11, 28, 35) We performed immunoprecipitation to evaluate the interaction of MCPIP1 with relevant substrates, including TRAF2, TRAF6, TANK, and HIF-1α. As expected, all molecules were co-immunoprecipitated by the MCPIP1 antibody (Fig. 5A ). We noticed a dramatic increase in the amount of HIF-1α protein co-immunoprecipitated with MCPIP1 after H/R treatment (Fig. 6A) . We confirmed the interaction of HIF-1α with MCPIP1 by co-immunoprecipitation with HA-HIF-1α or Flag-MCPIP1 (Fig. 5B) . Considering the essential role of HIF-1α in hypoxia stress, MCPIP1 may function by modulating HIF-1α in liver I/R injury. Indeed, HIF-1α protein was significantly upregulated following hypoxic treatment and gradually decreased in the liver postreperfusion (Fig. 5C) . Interestingly, sustained MCPIP1 expression in HTG mice maintained the HIF-1α protein at a relatively high level over time compared with NTG mice after I/R operation (Fig. 5C) . Accordingly, the mRNA expression of HIF-1α target genes, including Hmox-1 (heme oxygenase 1), Glut-1 (glucose transporter 1), and Vegf (vascular endothelial growth factor) (13, 14, 21) were significantly upregulated, whereas Hif-1α itself was not altered by MCPIP1 overexpression (Fig. 5D) . Furthermore, MCPIP1 overexpression was able to maintain HIF-1α protein expression in L02 cells undergoing H/R treatment (Fig. 5E) . Finally, we verified that MCPIP1 stabilized HIF-1α protein in the presence of protein synthesis inhibitor cycloheximide (CHX) (Fig. 5F ). These findings indicate that MCPIP1 binds to and maintains HIF-1α protein expression. The resultant L02 cells were also collected to detect the expression of different proteins. GAPDH served as the loading control. The resultant L02 cells were used for LDH (E) and MTT assay (F). For (B)-(F), three independent experiments in triplicate were performed. # indicates P < 0.05 compared with MCPIP1 groups; * indicates P < 0.05 compared with control groups. All data are presented as the mean ± SD; significance determined by one-way ANOVA. Abbreviations: IB, immunoblot; IP, immunoprecipitation.
DeuBIQuItINatINg eNZyMe aCtIVIty IS eSSeNtIal FoR MCpIp1 FuNCtIoN IN HepatIC I/R INJuRy
MCPIP1 is a deubiquitinating enzyme, (11) and HIF-1α is ubiquitinated and degraded through the proteasome pathway. (23, 24) Thus, we explored whether MCPIP1 stabilized HIF-1α through deubiquitination. Indeed, wild-type MCPIP1 was able to reduce HIF-1α ubiquitination, whereas mutant MCPIP1 (MCPIP1 C157A) that had lost its deubiquitination activity showed impaired ability to reduce HIF-1α ubiquitination (Fig. 6A) . As expected, overexpression of wild-type MCPIP1 in L02 cells undergoing H/R treatment reproduced the protective effect of MCPIP1 in HTG mice subjected to hepatic I/R operation, including stabilization of HIF-1α and induction of HIF-1α target genes (Fig. 6B) , suppression of p65 signaling, and expression of inflammatory cytokines/chemokines at the mRNA and protein levels (Fig. 6B-D) ; alleviated expression of pro-apoptosis factors and LDH release (Fig. 6B,D,E) ; and increased the expression of prosurvival factors and cell proliferation (Fig. 6B,D,F) . Notably, MCPIP1 C157A completely lost the ability to achieve the protective effect of wild-type MCPIP1 (Fig. 6B-F) . In fact, cells expressing MCPIP1 C157A exhibited more severe cell death and inflammation than control cells (Fig. 6B-F) . These observations indicate that deubiquitinating enzyme activity is required for MCPIP1 function in hepatic I/R injury. MCPIP1 may function by deubiquitinating and maintaining HIF-1α protein expression in this process.
HIF-1α MeDIateS MCpIp1 FuNCtIoN IN HepatIC I/R INJuRy
We further tested whether HIF-1α mediated MCPIP1 function in hepatic I/R injury by using 2MeOE2 (2-methoxyestradiol), which inhibits HIF-1α accumulation in the nucleus, (36) or DMOG, which inhibits prolyl-4-hydroxylase to stabilize HIF-1α. (37) As expected, HTG hepatocytes subjected to H/R treatment showed significantly increased induction of HIF-1α target genes compared with NTG hepatocytes (Fig. 7A) . Notably, HIF-1α inhibition by 2MeOE2 treatment efficiently normalized the induction of HIF-1α target genes in HTG primary hepatocytes comparable to that in NTG hepatocytes (Fig. 7A ). More importantly, 2MeOE2 treatment potently abrogated the suppressive effect of MCPIP1 on the mRNA expression of pro-inflammatory cytokines/chemokines and their production in the culture medium (Fig. 7A-B) . Consistently, 2MeOE2 treatment overwhelmed the function of MCPIP1 to repress the phosphorylation of multiple molecules of p65 signaling (Fig. 7C) . 2MeOE2 treatment aggravated cell death, as evidenced by decreased Bcl-2, increased cleaved Caspase 3 and Bax, and elevated LDH release in the culture medium (Fig. 7A,C,D) . Finally, 2MeOE2 abrogated MCPIP1 function to promote hepatocyte proliferation/regeneration (Fig. 7E) . In contrast, HIF-1α stabilization by DMOG treatment rescued the expression of HIF-1α target genes in HKO hepatocytes and sufficiently compensated for the detrimental effect of MCPIP1 deficiency on hepatic I/R injury, as evidenced by reduced expression of pro-inflammatory cytokines/chemokines (Fig. 8A,B) , inhibition of p65 signaling (Fig. 8C) , ameliorated expression of pro-apoptosis factor and LDH release (Fig. 8A,C,D) , and enhanced expression of prosurvival factors and cell proliferation/regeneration (Fig. 8A ,C,E) in HKO hepatocytes. Our findings suggest that HIF-1α mediates MCPIP1 function in hepatic I/R injury. MCPIP1 and HIF-1α may form a regulatory axis and play an important role in hepatic I/R injury.
Discussion
A CCCH zinc finger protein, MCPIP1 is a crucial regulator of immune response and plays an important role in a variety of inflammation-related diseases. (38) Considering that sterile inflammation is a hallmark of hepatic I/R injury, MCPIP1 may play an important role in this process. Indeed, we provided evidence showing that MCPIP1 was a pivotal regulator protecting against hepatic I/R injury. We demonstrated that MCPIP1 downregulation was closely related to hepatic I/R injury in liver transplantation patients and mouse models. MCPIP1 alleviated hepatocyte cell death, dampened inflammatory responses, and promoted survival of hepatocytes in hepatic I/R injury. Mechanistically, MCPIP1 interacted with and deubiquitinated HIF-1α, which ultimately stabilized The production of LDH in the culture medium was quantitated by ELISA. (E) Cells were also used for MTT assay to evaluate the cell proliferation. For (A)-(E), three independent experiments in triplicate were performed. * indicates P < 0.05 compared with DMSO NTG group; # indicates P < 0.05 compared with DMSO HTG group. All data are presented as the mean ± SD; significance determined by one-way ANOVA. Abbreviation: n.s., no significant difference. (E) Cells were also used for MTT assay to evaluate the cell proliferation. For (A)-(E), three independent experiments in triplicate were performed. * indicates P < 0.05 compared with the DMSO Flox group; # indicates P < 0.05 compared with the DMSO HKO group. All data are presented as the mean ± SD; significance determined by one-way ANOVA. Abbreviation: n.s., no significant difference.
HIF-1α protein. Inhibition of HIF-1α abolished the protective effect of MCPIP1, whereas HIF-1α stabilization compensated for the effect of MCPIP1 deficiency. These results clearly show that MCPIP1 and HIF-1α compose a regulatory axis that is amenable to manipulation for intervention of hepatic I/R injury.
A unique feature of MCPIP1 is that it contains both RNase and DUB activities. Both activities of MCPIP1 are involved in various biological functions, such as cellular RNA decay and negative regulation of cellular inflammation. For instance, MCPIP1 negatively regulates inflammation by degrading the mRNAs of Il-6 and Il-1. (10) MCPIP1 also inhibits NF-κB and JNK signaling pathways by removing ubiquitin moieties of TRAFs through its direct DUB activity. (12) In this study, we demonstrated that MCPIP1 may directly target HIF-1α through its DUB activity instead of RNase activity. We showed that the mRNA expression level of Hif-1α was not altered by MCPIP1 (Fig. 5D) . Instead, HIF-1α protein was deubiquitinated and maintained by wild-type MCPIP1 but not by MCPIP1 C157A, a mutant form of MCPIP1 that lost its deubiquitinating enzyme activity but retained its RNase activity. Furthermore, MCPIP1 C157A showed reduced ability to repress NF-κB signaling and inflammation. Thus, the deubiquitinating enzyme activity is critical for MCPIP1 function in hepatic I/R injury. It may be worth testing how the RNase activity of MCPIP1 contributes to MCPIP1 function in this process.
Multiple substrates of MCPIP1 have been identified, including TRAF2, TRAF6, TANK (family member-associated NF-κB activator), and HIF-1α. (11, 28, 35) As expected, we detected an interaction of MCPIP1 with all of these molecules. However, it is not clear which molecule mediates MCPIP1 function. We identified HIF-1α as a partner that mediates MCPIP1 function in hepatic I/R injury. HIF-1α is known to be a protective factor in human I/R injury and in multiple organ I/R injury models. (26, 27, 39) For instance, a meta-analysis demonstrated that HIF-1α attenuated liver I/R injury. (25) Loss or silencing of the PHD1 prolyl hydroxylase, leading to HIF-1α stabilization, protected the livers of mice against I/R injury. (40) HIF-1 also reduced myocardial I/R injury by targeting the mitochondrial permeability transition pore. (27) Consistent with these observations, we showed that HIF-1α inhibition abrogated the protective effect of MCPIP1. Furthermore, pharmaceutical stabilization of HIF-1α significantly ameliorated liver damage due to MCPIP1 deficiency. These observations suggest that HIF-1α is an important factor that mediates MCPIP1 function in hepatic I/R injury. Thus, MCPIP1 and HIF-1α may form a regulatory axis that appears to be amenable to manipulation. Targeting this MCPIP1-HIF-1α axis may be a potential strategy to prevent hepatic I/R injury. Nevertheless, our study does not exclude that other MCPIP1 substrates may contribute to the effects of MCPIP1. Systemic identification of MCPIP1 substrates in hepatic I/R injury will help reveal the panorama of MCPIP1 in this disease.
One potential obstacle for application of HIF-1α stabilizers for treatment of hepatic I/R injury in the clinic is that HIF-1α promotes cancer cell survival under hypoxic conditions in tumors. (21, 36) Our findings in this study may provide an alternative way to manipulate HIF-1α activity by MCPIP1. A recent report showed that MCPIP1 is subjected to proteolytic regulation by Malt1 in T cells. (41) MCPIP1 suppresses T-cell activation by cleaving mRNAs of multiple effector genes. T-receptor activation also induces Malt1 expression, which cleaves MCPIP1 and causes MCPIP1 degradation. In this way, T cells might maintain activation at a controllable level. Treatment with Malt1 protease inhibitor stabilizes a set of effector genes and suppresses immune activation. Therefore, it is tempting to speculate that the MCPIP1 activity can be modulated by inhibiting Malt1-mediated cleavage of MCPIP1. It will be very interesting to test whether Malt1 expression is correlated to hepatic I/R injury and how Malt1 may function in this process.
In conclusion, our study indicates that MCPIP1 is a protective factor in hepatic I/R injury. The protective effects of MCPIP1 in hepatic I/R injury are at least partly mediated by the HIF-1α-dependent pathway. Targeting MCPIP1 could represent a therapeutic approach to significantly dampen hepatic I/R injury and thereby improve outcomes during liver transplantation. 
